Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff? These researchers think so

When Exelixis CEO Michael Morrissey rolled out the biotech's final numbers for 2025 earlier in the year, there was no mistaking the outsized role that cabozantinib played in funding the company and keeping its stock ...